Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Katapult Holdings reported a net income of $51.3 million for the nine months ended September 30, 2026, a significant improvement from the prior year, driven by a 23.8% increase in total revenues to $1.62 billion. The company's balance sheet expanded substantially following a reverse merger, with total assets growing from $1.4 billion to $3.1 billion and cash reserves increasing to $261.0 million.
Loop Industries received a deficiency notice from Nasdaq on November 9, 2026, for failing to maintain the minimum Market Value of Publicly Held Shares (MVPHS) of $15 million for 30 consecutive business days. The company has 180 calendar days, until May 10, 2027, to regain compliance by maintaining a MVPHS of at least $15 million for ten consecutive business days. The notice does not have an immediate effect on the listing of the company's common stock.
Indaptus Therapeutics reported a net loss of $5.38 million for the nine months ended September 30, 2026, a significant reduction from the $12.74 million loss in the prior year period. The company's cash position strengthened to $26.60 million following significant common stock issuances and preferred stock conversions, while operating expenses decreased across both R&D and G&A categories.
The Goodyear Tire & Rubber Company has called for the redemption of $700 million in aggregate principal amount of its 4.875% Senior Notes due 2027. The redemption is scheduled for December 15, 2026, at a price equal to 100% of the principal amount plus accrued and unpaid interest.
BIO-key International reported Q3 2026 financial results, highlighted by a 39% increase in software license fee revenue to $1.3 million and a gross margin improvement to 90%. The company narrowed its quarterly net loss to $0.89 million and retired its remaining outstanding debt, leaving the firm effectively debt-free.
Term
Q3 2026
“Our Q3’26 results reflect the building strength of our core software business. Software license fee revenue grew 39% in Q3’26, offsetting variability in our more episodic hardware and services revenue and lifting gross margin to 90% from 77% a year ago.”
Mike DePasquale, CEO
“Year to date we have grown revenue by 14%, reduced our net loss by 42% and we retired our remaining note outstanding leaving us effectively debt free.”
Perspective Therapeutics CMO Markus Puhlmann Buys $29.6K of Stock
Markus Puhlmann, CMO, bought 35,000 shares of Perspective Therapeutics, Inc. at $0.8447 a share, worth $29.6K in total on Nov 12, 2026. Shares held after the trade: 178,542 (+24.4%).
James Hardie Industries Insider Jesse G. Singh Sells $720K of Stock
Jesse G. Singh sold 25,000 shares of James Hardie Industries plc at $28.82 a share, worth $720K in total on Nov 11, 2026. Shares held after the trade: 333,797 (-7.0%).
NXP Semiconductors EVP, Chief Sales Officer Andrew Hardy Sells $438K of Stock
Andrew Hardy, EVP, Chief Sales Officer, sold 1,643 shares of NXP Semiconductors N.V. at $266.49 a share, worth $438K in total on Nov 11, 2026. Shares held after the trade: 4,064 (-28.8%).
Prospect Capital CEO John F. Barry Buys $6.05M of Stock
John F. Barry, CEO, bought 4,014,895 shares of Prospect Capital Corp at $1.51 to $1.51 a share (average $1.51) in 2 transactions, worth $6.05M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 95,808,672 (+1.5%).
Cineverse Corp. reported a significant revenue increase to $25.96 million for the quarter ended September 30, 2026, compared to $12.36 million in the prior year, driven by business growth and acquisition-related fair value adjustments. The company achieved a net income of $3.25 million for the quarter, a substantial improvement from a net loss of $5.55 million in the same period of 2025.
FRP Holdings, Inc. reported a net loss of $1.11 million for the nine months ended September 30, 2026, compared to a net income of $2.95 million in the prior year period. The decline was driven by increased general and administrative expenses and higher equity losses from joint ventures, despite a slight increase in total revenues to $32.64 million.
Benitec Biopharma reported a net loss of $12.9 million for the quarter ended September 30, 2026, compared to $9.0 million in the prior year period, primarily driven by a significant increase in research and development expenses for their BB-301 program. The company maintained a strong liquidity position with $176.4 million in cash and cash equivalents to fund ongoing clinical development.
Quantum Cyber reported its first revenue of approximately $1.0 million for Q3 2026 following its strategic pivot to autonomous defense. The company also announced an $8.0 million funding commitment from CEO David Lazar to support the build-out of its Bridgeport manufacturing facility and technology programs.
Counterparty
David Lazar
“The third quarter of 2026 is the quarter in which Quantum Cyber crossed from a pre-revenue strategy into an operating company. We generated our first revenue, we installed the first production equipment at our Bridgeport facility, and we resolved a legacy legal claim that had overhung our capital structure.”
David Lazar, Chief Executive Officer
“The $8.0 million funding commitment I provided to the Company on November 11, 2026 is intended to reinforce the balance sheet while we complete the build-out of the Bridgeport facility and continue to advance the Project LightShift quantum antenna program under our newly expanded field of use.”
Aardvark Therapeutics reported Q3 2026 financial results and announced that the FDA has lifted the clinical hold on its lead candidate ARD-101 for Prader-Willi Syndrome. The company ended the quarter with $60.3 million in cash, which is expected to fund operations through 2027 as it prepares for a clinical development meeting with the FDA in early 2027.
Term
Q3 2026
“The lifting of the clinical hold and the FDA’s agreement that we may conduct an open-label trial at 200 mg twice daily are important steps toward resuming clinical development of ARD-101 in PWS. We have developed a proposed clinical development plan and look forward to discussing it with the FDA. We remain committed to advancing ARD-101 for patients and families affected by PWS.”
Tien Lee, M.D., Founder and Chief Executive Officer
Fortress Biotech reported a significant net income of $129.5 million for the nine months ended September 30, 2026, primarily driven by a $158.9 million gain on the sale of a priority review voucher. This represents a substantial turnaround from the $27.5 million net loss in the prior year period, while total assets grew to $280.2 million.
Cineverse reported Q2 FY 2027 revenue of $26.0 million, a 110% year-over-year increase driven by its technology and media services segments. The company achieved net income of $3.2 million and its third consecutive quarter of positive Adjusted EBITDA, while reaffirming full-year revenue guidance of $115 million to $120 million.
Titan International provided supplemental historical financial information for the first and second quarters of 2026 and 2025, recast to reflect its ITM business as discontinued operations following a sale agreement. The filing includes formal GAAP income statements for these periods to assist investors in evaluating the company's continuing operations.
Transglobal Management Group M&A Deal with Third Life World, LLC
Transglobal Management Group completed its acquisition of the Third Life World platform and technology from Third Life World, LLC. In a related change of control transaction, Third Life World acquired 200 shares of Series A Preferred Stock (representing 80% voting power) from Marc Angell for $140,000. Jorge Guinovart, managing member of Third Life World, has been appointed as the company's new CEO and President.
Revvity is hosting its 2026 Investor Day to showcase its 'Powering Scientific Intelligence' strategy, focusing on AI-enabled discovery workflows and its Life Sciences and Diagnostics portfolio. Management will outline strategic priorities, operational initiatives, and the company's long-range financial outlook to investors.
Biofrontera Inc. reported Q3 2026 net product revenue of $9.1 million, a 30% year-over-year increase driven by its photodynamic therapy products. The company achieved a significant regulatory milestone with the FDA approval of Ameluz for the treatment of superficial basal cell carcinoma. Net loss for the quarter narrowed slightly to $6.4 million compared to $6.6 million in the prior-year period.
Term
Q3 2026
“The third quarter was a pivotal one for Biofrontera. On September 9, the FDA approved Ameluz® PDT for the treatment of superficial basal cell carcinoma (sBCC), making it the first PDT approved in the United States for a cancerous skin tumor. Five days later, U.S. Customs and Border Protection ruled that our redesigned RhodoLED® XL-C is not subject to the ITC exclusion order, which allows us to again serve the customers who rely on our large-field lamp.”
Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera
DeltaSoft Corp. reported a net loss of $15,113 for the six months ended September 30, 2026, on revenues of $11,299. The company is in the development stage with an accumulated deficit of $16,022 and faces a going concern uncertainty due to limited working capital and reliance on future investment capital.
Medalist Diversified, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $20.96 million compared to a net loss of $1.59 million in the prior year, primarily driven by a $21.19 million gain on the disposal of investment properties. Total assets decreased from $77.74 million to $52.29 million as the company shifted its portfolio, including a substantial increase in marketable securities and a reduction in mortgage debt.
Owlet reported Q3 2026 revenue of $30.4 million and achieved positive net income of $1.4 million, driven by gross margin expansion and growth in its subscription service. However, the company withdrew its full-year 2026 financial outlook due to a safety update for its camera cable guard accessory, which is expected to cause retail sales interruptions and remediation expenses in Q4.
Term
Q3 2026
“We delivered a strong third quarter, driven by our focus on profitable growth. Revenue of $30.4 million was in line with our expectations, we expanded gross margin by 315 basis points, generated positive operating income and operating cash flow, and delivered $3.5 million of Adjusted EBITDA.”
Kurt Workman, Owlet’s President, Chief Executive Officer, and Co-Founder
“Today, we initiated a camera cable guard safety update for the cable guard accessory. We are providing a replacement enclosed cable guard system that we believe delivers on our commitment to elevating safety standards in the market.”
Kurt Workman, Owlet’s President, Chief Executive Officer, and Co-Founder
For the nine months ended September 30, 2026, Allarity Therapeutics reported a net loss of $12.4 million, an increase from the $7.9 million loss in the prior year period, primarily driven by higher research and development costs. The company's total stockholders' equity turned to a deficit of $2.3 million as of September 30, 2026, while cash and restricted cash increased to approximately $24.1 million.
Fortress Biotech reported Q3 2026 financial results with total net revenue increasing 9% year-over-year to $19.2 million. During the quarter, the company repaid its Oaktree credit facility in full, leaving it with no outstanding debt at the parent level, and in-licensed FB-607 for the treatment of IBS-D.
Term
Q3 2026
“The third quarter of 2026 reflected continued execution across our diversified portfolio. In September, we repaid in full our credit facility with Oaktree and we also recently announced the in-licensing of FB-607, a novel combination therapy to treat the symptoms of irritable bowel syndrome with diarrhea (“IBS-D”).”
Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer
“With our growing royalty income from ZYCUBO® and UNLOXCYT™, and multiple potential catalysts across our partnered programs, we believe Fortress is well positioned to continue driving long-term value for our shareholders.”
Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer
PAVmed reported preliminary Q3 2026 financial results, highlighted by its subsidiary Lucid Diagnostics securing nationwide Medicare reimbursement for the EsoGuard test. The company reported $1.2 million in revenue for the quarter and noted that October saw record test volume of over 1,800 tests.
Term
Q3 2026
“We’re very encouraged by developments across the PAVmed portfolio. Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone. As Lucid’s largest common shareholder, PAVmed stands to benefit directly from Lucid’s substantial near-term revenue opportunity. Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are also now actively engaged with FDA on both PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value.”
Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer
PDS Biotechnology reported third quarter 2026 financial results, highlighting a strategic shift to PDS0301 as its lead development program. The company also noted the initial closing of a $22.3 million PIPE financing led by Nant Capital and the appointment of several new board members, including Dr. Patrick Soon-Shiong.
“During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program. We believe the ongoing clinical trials of PDS0301 at the NCI, along with those of our cancer vaccine platform, support our view that targeted T cell immunotherapy has the potential to change how solid tumors are treated.”
Frank Bedu-Addo, PhD, President and Chief Executive Officer
Benitec Biopharma reported financial results for its first fiscal quarter ended September 30, 2026, and announced a change in its fiscal year-end from June 30 to December 31. The company highlighted a 100% responder rate in its ongoing Phase 1b/2a study of BB-301 for OPMD and confirmed it remains on track to begin a pivotal trial in mid-2027.
Term
Q1 2027
“The consistency and durability of the clinical benefit observed to date continues to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”
Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
Smartbird, Inc. announced it has secured data center capacity to accelerate the deployment of its AI infrastructure at scale. The company is transitioning from vision to execution by establishing a technology partner network with Supermicro and WEKA to provide integrated, rack-scale AI computing and data solutions.
Edible Garden AG Inc. has filed a Certificate of Amendment to effect a 1-for-5 reverse stock split of its common stock, effective November 17, 2026. The split will consolidate every five shares into one share to increase the per-share trading price, while the total number of authorized shares and par value remain unchanged. Trading on a post-split basis will begin under the existing symbol 'EDBL' at the market open on the effective date.